Galaxy Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2020-01-01
- Employees
- 1
- Market Cap
- -
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 3:1
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Not Applicable
1 (50.0%)Phase 3
1 (50.0%)SEAL™ME: Saccular Endovascular Aneurysm Lattice System Multicenter Enrollment Global Registry
Recruiting
- Conditions
- AneurysmAneurysm, Ruptured
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-04-04
- Lead Sponsor
- Galaxy Therapeutics INC
- Target Recruit Count
- 200
- Registration Number
- NCT05880680
- Locations
- 🇨🇴
Angiosur, Itagüi, Medellín, Colombia
🇳🇿Auckland City Hospital, Auckland, New Zealand
🇵🇰Punjab Institute of Neuroscience (PINS), Lahore, Pakistan
SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial
Phase 3
Recruiting
- Conditions
- Intracranial Aneurysm
- First Posted Date
- 2023-04-26
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Galaxy Therapeutics INC
- Target Recruit Count
- 279
- Registration Number
- NCT05831202
- Locations
- 🇺🇸
Stony Brook University Hospital, Stony Brook, New York, United States
🇺🇸Endeavor Health - Northwest Community Hospital, Arlington Heights, Illinois, United States
🇺🇸Endeavor Health - Evanston Hospital, Evanston, Illinois, United States
Pre-SEAL™IT: Saccular Endovascular Aneurysm Lattice System First In Human Interventional Trial
Not Applicable
Completed
- Conditions
- Aneurysm, RupturedAneurysmAneurysms Saccular
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Galaxy Therapeutics INC
- Target Recruit Count
- 26
- Registration Number
- NCT05686733
- Locations
- 🇨🇴
Clinicas Las Americas, Medellin, Antioquia, Colombia
News
No news found